Slide 1: FY 2015 Results
FY 2015 Results 09 March 2016 DiaSorin
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Overview
Overview Highlights FY 2015 Main Topics Revenues Revenues: Breakdown by Technology Revenues: Breakdown by Geography Installed Base Expansion Profitability Profile Business and Product Development FY 2015 Financials FY 2016 Company Guidance FY 2015 Results 3
Slide 4: Highlights
Highlights
Slide 5: FY 2015 Main Topics
FY 2015 Main Topics CHANGE YOY CHANGE YOY REVENUES: €/mln 499.2 +12.5% LIAISON & LIAISON XL PLACEMENTS: +464 @ CER +6.0% LIAISON XL +627 CLIA ex Vit D 25 OH: +23.5% Ongoing worldwide success of LIAISON XL @ CER +18.5% LIAISON -163 Positive performance in all clinical areas mainly driven by Infectiou
Slide 6: Revenues
Revenues Q4’15 FY’15 vs. vs. Q4’14 FY’14 Growth driven by all CLIA tests, in particular Infectious Diseases, Torch, Stool Testing and Vitamin D 1,25. @ current +10.9% +12.5% Positive impact of Quest agreement on Vitamin D 25 OH Revenues sales and growth in Germany and Italy have offset Australia and
Slide 7: Revenues: Breakdown by Technology
Revenues: Breakdown by Technology FY 2014 FY 2015 CLIA tests CLIA tests 70.6% 74.4% ELISA + RIA ELISA + RIA tests tests Molecular Diagnostics 16.7% Molecular Diagnostics tests tests 13.3% Instruments & Instruments & 0.7% Consumables 0.8% Consumables 12.0% 11.5% FY 2015 Results 7
Slide 8: Revenues: Breakdown by Technology
Revenues: Breakdown by Technology Q4’15 FY’15 vs. vs. Q4’14 FY’14 @ current +21.9% +23.5% Growth across all CLIA ex Vitamin D 25 OH tests, in CLIA ex Vitamin D particular Infectious Diseases, Hepatitis & Retrovirus, 25 OH tests Torch, Stool Testing and Vitamin D 1,25. @ CER +18.7% +18.5% CLIA @ curr
Slide 9: Revenues: Breakdown by Geography
Revenues: Breakdown by Geography EUROPE 235.3 €/MLN NORTH AMERICA 47.1% of sales 127.8 €/MLN +5.7% 25.6% of sales +3.2% CLIA EX VIT D 25 OH GERMANY FRANCE +41.5% +9.5% -4.0% VIT D 25 OH +0.0% ITALY CHINA +2.1% +30.2% ASIA PACIFIC MEXICO 97.4 €/MLN +9.2% BRAZIL 19.5% of sales -10.8% +14.8% LATIN AMER
Slide 10: Revenues: Breakdown by Geography
Revenues: Breakdown by Geography Q4’15 FY’15 Q4’15 FY’15 vs. vs. vs. vs. Q4’14 FY’14 Q4’14 FY’14 Solid and continuous growth on all CLIA EUROPE +7.7% +5.7% Germany +11.5% +9.5% products. Good performance of Stool testing, Vitamin D 25 OH and Vitamin D 1,25. Increase driven by Infectious Diseases, It
Slide 11: Revenues: Breakdown by Geography
Revenues: Breakdown by Geography Q4’15 FY’15 Q4’15 FY’15 vs. vs. vs. vs. Q4’14 FY’14 Q4’14 FY’14 ASIA Increase in sales driven by all CLIA tests, +10.0% +14.8% China +26.1% +30.2% PACIFIC particularly Hepatitis & Retrovirus, Torch and Infectious Diseases. Continuous success of LIAISON XL. Slowdown o
Slide 12: Installed Base Expansion
Installed Base Expansion TOTAL UNITS AT TOTAL UNITS AT NET PLACEMENTS DECEMBER 31, DECEMBER 31, IN 2015 2014 2015 4,207 -163 4,044 1,665 +627 2,292 TOTAL 5,872 +464 6,336 FY 2015 Results 12
Slide 13: Profitability Profile
Profitability Profile Q4’14 Q4’15 FY’14 FY’15 EBITDA 35.8% 37.1% +130 bps 36.1% 37.1% +100 bps margin Value in €/mln FY 2015 EBITDA has been negatively affected by high “Other operating expenses” FY’14 FY’15 Miscellaneous tax charges, of which €1.3m due to US Medical Device Tax (1.9) (2.0) Bad debt
Slide 14: Business and Product Development
Business and Product Development
Slide 15: Business and Product Development
Business and Product Development BUSINESS DEVELOPMENT Sonic Healthcare Renewal of agreement on >15 CLIA tests Quest Diagnostics 5 years agreement for the commercialization of Vitamin D 25 OH Distribution partnership agreement for the commercialization in China of Hepatitis B, C and HIV tests on LIAI
Slide 16: FY 2015 Financials
FY 2015 Financials
Slide 17: Income Statement
Income Statement FY Change Data in € million 2014 2015 amount % Net revenues 443.8 499.2 +55.4 +12.5% Gross profit 298.7 341.9 +43.2 +14.4% Gross Margin 67.3% 68.5% +120 bps S&M (88.9) (98.0) -9.1 +10.2% R&D (25.0) (26.2) -1.2 +4.7% G&A (50.6) (55.5) -4.9 +9.7% Total operating expenses (164.5) (179.
Slide 18: Balance Sheet
Balance Sheet Data in € million 12/31/2014 12/31/2015 Change Total intangible assets 117.0 117.9 +1.0 Total tangible assets 72.2 74.5 +2.3 Other non-current assets 25.6 21.2 -4.4 Net Working Capital 142.3 144.0 +1.7 Other non-current liabilities (39.8) (38.3) +1.5 Net Capital Employed 317.2 319.2 +2
Slide 19: Cash Flow Statement
Cash Flow Statement Data in € million 2014 2015 Change Cash and cash equivalents at the beginning of the period 105.1 144.9 +39.7 Operating activities 119.8 138.4 +18.6 Investing activities (28.9) (30.5) -1.6 Financing activities (29.5) (8.2) +21.3 Acquisitions of companies and business operations 0
Slide 20: FY 2016 Company Guidance
FY 2016 Company Guidance
Slide 21: FY 2016 Company Guidance
FY 2016 Company Guidance Revenues Growth between +5% and +6% at CER vs. FY’15 Revenues EBITDA Growth between +6% and +7% at CER vs. FY’15 EBITDA Title ofResults FY 2015 presentation 21
Slide 22: DiaSorin
DiaSorin The Diagnostic Specialist